19 June 2017


Sareum Holdings PLC

(“Sareum” or the “Company”)

Sareum to Present at the International Cancer Cluster Showcase 2017

Dr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will deliver a presentation at the 6th annual International Cancer Cluster Showcase, being held today at the San Diego Convention Center.

Dr Mitchell will be showcasing Sareum and its cancer research pipeline as one of three companies from the UK “Golden Triangle” biotechnology cluster.

Companies from nine North American and European innovation hubs are scheduled to present at the event, which is organised as a satellite to the BIO International Convention, the world’s largest gathering for the global biotech industry. Over 200 representatives from the international oncology community are expected to participate in this focused network meeting.


Dr Tim Mitchell, CEO of Sareum, commented: “We are delighted that Sareum has been selected to represent British cancer research at this prestigious event.”

For further information, please contact:

Sareum Holdings plc


Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Co-Broker)


Claire Noyce

020 3764 2341

The Communications Portfolio (Sareum Media enquiries)


Ariane Comstive

07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk